Skip to main content

HORMESIS INDUCIDA POR RADIACION EN ONCOLOGIA

PID2019-110369RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD CARLOS III DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study

  • Sala-Vila, Aleix
  • Tristão Pereira, Catarina
  • Lázaro, Iolanda
  • Shekari, Mehrnaz
  • Fernández-Pena, Alberto
  • Monereo-Sánchez, Jennifer
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Sánchez González, Javier
  • Gispert, Juan Domingo
  • Ibáñez, Borja
  • Fuster, Valentín
  • Cortes-Canteli, Marta
Background: Excess energy intake upregulates de novo lipogenesis (DNL). Circulating palmitoleic acid (POA) is an objective DNL biomarker associated with higher cardiovascular risk, which has been linked to cerebral hypometabolism. Whether POA also relates to altered cerebral glucose metabolism in midlife remains unknown. Objectives: This study aimed to examine cross-sectional and longitudinal associations between circulating POA (predictor) and cerebral glucose hypometabolism (outcome), a neuroimaging marker linked to increased risk of subsequent cognitive decline. Methods: We studied 461 middle-aged [median age, 51 (47-54) y] individuals with subclinical atherosclerosis from the Progression of Early Subclinical Atherosclerosis (PESA) study, a longitudinal observational cohort of asymptomatic individuals (NCT01410318). Red blood cell (RBC) POA was quantified by gas chromatography in blood samples collected at 2 visits of PESA participants who had undergone longitudinal cerebral 18F-fluorodeoxyglucose (FDG) positron emission tomography (4.9 y of follow-up time). Dietary data were derived from a validated food-frequency questionnaire. Associations were assessed using region-of-interest and voxelwise multiple regression models as well as mediation analysis. Results: Cross-sectionally, higher RBC POA was associated with widespread lower FDG uptake across the brain [β = -0.119 (95% confidence interval: -0.206, -0.032), P = 0.007], even after adjusting for cardiovascular risk. Longitudinally, participants with sustained high RBC POA exhibited a 65% greater decline in cerebral FDG uptake compared with those with sustained low POA [β = -0.403 (-0.744, -0.063), P = 0.021], particularly in frontal and parietal regions. RBC POA concentrations were higher among individuals adhering to the predefined "Social-Business" dietary pattern and were significantly associated with increased alcohol intake. Furthermore, the association between alcohol intake and subsequent precuneus hypometabolism was partially mediated by RBC POA concentrations. Conclusions: RBC POA, a marker of DNL, is associated with cerebral glucose hypometabolism, supporting that healthy dietary habits in midlife are key to preserving brain health. This trial was registered at clinicaltrials.gov as NCT01410318., The Progression of Early Subclinical Atherosclerosis study is funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Santander Bank, and also receives funding from the European Regional Development Fund (ERDF–A Way to Build Europe), and the European Social Fund (ESF–Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033) and is supported by the Carlos III Institute of Health (ISCIII), the Ministry of Science and Innovation, and the Pro CNIC Foundation. AS-V was supported by ISCIII, through the project PI22/00071, co-funded by European Regional Development Fund “Investing in your future.” CT-P was supported by a “la Caixa” Foundation fellowship (LCF/BQ/DI19/11730052). BI was supported by the European Commission (ERC-CoG 819775, and H2020-HEALTH 945118), the Spanish Ministry of Science and Innovation (PID2019-110369RB-I00), and the Community of Madrid (P2022/BMD-7403, RENIM-CM). Acknowledgment is made to the Sephardic Foundation on Aging and other donors of the Alzheimer’s Disease Research (Grant Number A2022034S), a program of the BrightFocus Foundation, for the partial support of this research. This work was supported by the Cardiovascular Risk Factors and Brain Health Program at CNIC. The funding agencies had no role in the study design, data collection, analysis, decision to publish, or manuscript preparation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neutrophil β1 adrenergic receptor blockade blunts stroke-associated neuroinflammation

  • Clemente-Moragón, Agustín
  • Oliver, Eduardo
  • Calle, D.
  • Cussó, Lorena
  • Gómez Tech, Mónica
  • Pradillo, Jesús M.
  • Castejón, Raquel
  • Rallón, Norma
  • Benito, José Miguel
  • Fernández-Ferro, José C.
  • Carneado-Ruíz, Joaquín
  • Moro, María A.
  • Sánchez-González, Javier
  • Fuster, Valentín
  • Cortés-Canteli, Marta
  • Desco, Manuel
  • Ibáñez, Borja
39 p.-7 fig.-1 graph. abst., Background and Purpose Reperfusion therapy is the standard of care for ischemic stroke; however, there is a need to identify new therapeutic targets able to ameliorate cerebral damage. Neutrophil´s β1 adrenergic receptor (β1AR) has been linked to migration during exacerbated inflammation. Given the central role of neutrophils in cerebral damage during stroke, we hypothesize that β1AR blockade will improve stroke outcomes., Experimental Approach Rats were subjected to middle cerebral artery occlusion–reperfusion to evaluate the effect on stroke of the selective β1AR blocker metoprolol (12.5 mg/Kg) when injected i.v. 10 min before reperfusion., Key Results Magnetic resonance imaging and histopathology analysis showed that pre-reperfusion i.v. metoprolol reduced IS. This was accompanied by reduced cytotoxic edema at 24 h and vasogenic edema at 7 d. Metoprolol-treated rats showed reduced brain neutrophil infiltration and those which infiltrated displayed a high proportion of anti-inflammatory phenotype (N2, YM1+). Additional inflammatory models demonstrated that metoprolol specifically blocked neutrophil migration via β1AR and excluded a significant effect on glia compartment. Consistently, metoprolol did not protect the brain in neutrophil-depleted rats upon stroke. In patients suffering an ischemic stroke, β1AR blockade by metoprolol reduced circulating neutrophil–platelet co-aggregates., Conclusions and Implications Our findings describe that β1AR blockade ameliorates cerebral damage by targeting neutrophils, identifying a novel therapeutic target to improve outcomes in patients with stroke. This therapeutic strategy is in the earliest stages of the translational pathway and should be further explored., This study received funding from the Instituto de Salud Carlos III (ISCIII; PI16/02110 to B.I and PT20/00044 to MD), the European Regional Development Fund (ERDF) “A way of making Europe", the Comunidad de Madrid (S2017/BMD-3867 RENIM-CM to MD and BI) cofunded with European structural and investment funds and by Agencia Estatal de Investigación (PID2019‐110369RB‐I00 to B.I). BI is a recipient of funding from the European Research Council (ERC) under the European Union Horizon 2020 Research and Innovation Programme (ERC-Consolidator Grant agreement No. 819775). EO is a recipient of funds from the Comunidad de Madrid Programa de Atracción de Talento (2017-T1/BMD 5185) and from a Ramón y Cajal grant (RYC2020-028884-I) funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”. ACM is the beneficiary of an FPU fellowship from the Ministerio de Ciencia e Innovación (FPU2017/01932). MCC is the beneficiary of a Miguel Servet contract (MS16/00174). The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovación and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2020-001041-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study

  • Sala-Vila, Aleix
  • Tristão Pereira, Catarina
  • Lázaro, Iolanda
  • Shekari, Mehrnaz
  • Fernández-Pena, Alberto
  • Monereo-Sánchez, Jennifer
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Sánchez González, Javier
  • Gispert, Juan Domingo
  • Ibáñez, Borja
  • Fuster, Valentín
  • Cortes-Canteli, Marta
Background: Excess energy intake upregulates de novo lipogenesis (DNL). Circulating palmitoleic acid (POA) is an objective DNL biomarker associated with higher cardiovascular risk, which has been linked to cerebral hypometabolism. Whether POA also relates to altered cerebral glucose metabolism in midlife remains unknown. Objectives: This study aimed to examine cross-sectional and longitudinal associations between circulating POA (predictor) and cerebral glucose hypometabolism (outcome), a neuroimaging marker linked to increased risk of subsequent cognitive decline. Methods: We studied 461 middle-aged [median age, 51 (47-54) y] individuals with subclinical atherosclerosis from the Progression of Early Subclinical Atherosclerosis (PESA) study, a longitudinal observational cohort of asymptomatic individuals (NCT01410318). Red blood cell (RBC) POA was quantified by gas chromatography in blood samples collected at 2 visits of PESA participants who had undergone longitudinal cerebral 18F-fluorodeoxyglucose (FDG) positron emission tomography (4.9 y of follow-up time). Dietary data were derived from a validated food-frequency questionnaire. Associations were assessed using region-of-interest and voxelwise multiple regression models as well as mediation analysis. Results: Cross-sectionally, higher RBC POA was associated with widespread lower FDG uptake across the brain [β = -0.119 (95% confidence interval: -0.206, -0.032), P = 0.007], even after adjusting for cardiovascular risk. Longitudinally, participants with sustained high RBC POA exhibited a 65% greater decline in cerebral FDG uptake compared with those with sustained low POA [β = -0.403 (-0.744, -0.063), P = 0.021], particularly in frontal and parietal regions. RBC POA concentrations were higher among individuals adhering to the predefined "Social-Business" dietary pattern and were significantly associated with increased alcohol intake. Furthermore, the association between alcohol intake and subsequent precuneus hypometabolism was partially mediated by RBC POA concentrations. Conclusions: RBC POA, a marker of DNL, is associated with cerebral glucose hypometabolism, supporting that healthy dietary habits in midlife are key to preserving brain health. This trial was registered at clinicaltrials.gov as NCT01410318., The Progression of Early Subclinical Atherosclerosis study is funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Santander Bank, and also receives funding from the European Regional Development Fund (ERDF–A Way to Build Europe), and the European Social Fund (ESF–Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033) and is supported by the Carlos III Institute of Health (ISCIII), the Ministry of Science and Innovation, and the Pro CNIC Foundation. AS-V was supported by ISCIII, through the project PI22/00071, co-funded by European Regional Development Fund “Investing in your future.” CT-P was supported by a “la Caixa” Foundation fellowship (LCF/BQ/DI19/11730052). BI was supported by the European Commission (ERC-CoG 819775, and H2020-HEALTH 945118), the Spanish Ministry of Science and Innovation (PID2019-110369RB-I00), and the Community of Madrid (P2022/BMD-7403, RENIM-CM). Acknowledgment is made to the Sephardic Foundation on Aging and other donors of the Alzheimer’s Disease Research (Grant Number A2022034S), a program of the BrightFocus Foundation, for the partial support of this research. This work was supported by the Cardiovascular Risk Factors and Brain Health Program at CNIC. The funding agencies had no role in the study design, data collection, analysis, decision to publish, or manuscript preparation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF), a double blind, placebo-controlled, randomized clinical trial

  • García-Álvarez, Ana|||0000-0002-1718-2424
  • Blanco, Isabel|||0000-0001-9452-3432
  • García-Lunar, Inés
  • Jordà, Paloma|||0000-0002-9236-1713
  • Rodriguez-Arias, Juan J.
  • Fernández-Friera, Leticia
  • Zegrí-Reiriz, Isabel|||0000-0001-9742-8537
  • Nuche, Jorge
  • Gomez-Bueno, Manuel
  • Prat, Susanna
  • Pujadas, Sandra|||0000-0001-5232-4865
  • Solé González, Eduard|||0000-0002-5727-9925
  • Garcia-Cossio, Maria D.
  • Rivas, Mercedes
  • Torrecilla, Estefanía
  • Pereda, Daniel
  • Sánchez González, Javier|||0000-0003-1427-3870
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Segovia, Javier|||0000-0002-4606-3416
  • Delgado-Jiménez, Juan Francisco|||0000-0002-5401-8324
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
  • Fuster, Valentín
  • Barberà i Mir, Joan Albert|||0000-0003-1469-4990
  • Ibañez, Borja|||0000-0002-5036-254X
Aims: Pulmonary hypertension (PH) associated with left heart disease is an increasingly prevalent problem, orphan of targeted therapies, and related to a poor prognosis, particularly when pre- and post-capillary PH combine. The current study aimed to determine whether treatment with the selective β3 adrenoreceptor agonist mirabegron improves outcomes in patients with combined pre- and post-capillary PH (CpcPH). Methods and results: The β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure (SPHERE-HF) trial is a multicentre, randomized, parallel, placebo-controlled clinical trial that enrolled stable patients with CpcPH associated with symptomatic heart failure. A total of 80 patients were assigned to receive mirabegron (50 mg daily, titrated till 200 mg daily, n = 39) or placebo (n = 41) for 16 weeks. Of them, 66 patients successfully completed the study protocol and were valid for the main analysis. The primary endpoint was the change in pulmonary vascular resistance (PVR) on right heart catheterization. Secondary outcomes included the change in right ventricular (RV) ejection fraction by cardiac magnetic resonance or computed tomography, other haemodynamic variables, functional class, and quality of life. The trial was negative for the primary outcome (placebo-corrected mean difference of 0.62 Wood units, 95% confidence interval [CI] -0.38, 1.61, p = 0.218). Patients receiving mirabegron presented a significant improvement in RV ejection fraction as compared to placebo (placebo-corrected mean difference of 3.0%, 95% CI 0.4, 5.7%, p = 0.026), without significant differences in other pre-specified secondary outcomes. Conclusions: SPHERE-HF is the first clinical trial to assess the potential benefit of β3 adrenergic agonists in PH. The trial was negative since mirabegron did not reduce PVR, the primary endpoint, in patients with CpcPH. On pre-specified secondary outcomes, a significant improvement in RV ejection fraction assessed by advanced cardiac imaging was found, without differences in functional class or quality of life.